Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
LAEKNA-B Once Leaps ~40% After Signing Clinical Collaboration Agreement with Lilly for Obesity Drug
Recommend 4 Positive 8 Negative 3 |
||||
|
||||
|
LAEKNA-B (02105.HK) opened 0.94% lower today (20th) but managed to make a rebound, peaking at $14.54 with an uptick of 37%. It last printed at $13.22, up 24.72%, on a volume of 26.1037 million shares, involving $338 million. LAEKNA-B had previously announced a clinical collaboration agreement with Eli Lilly and Company (LLY.US) to support and accelerate global clinical development of LAE102 for the treatment of obesity. Lilly will be responsible for the execution and funding of a phase I study in the US, while LAEKNA-B retains global rights for LAE102. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
